Annual Current Liabilities
$15.30 M
+$2.77 M+22.10%
September 30, 2024
Summary
- As of February 7, 2025, AVXL annual total current liabilities is $15.30 million, with the most recent change of +$2.77 million (+22.10%) on September 30, 2024.
- During the last 3 years, AVXL annual current liabilities has risen by +$4.51 million (+41.72%).
- AVXL annual current liabilities is now at all-time high.
Performance
AVXL Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$15.30 M
+$3.55 M+30.20%
September 30, 2024
Summary
- As of February 7, 2025, AVXL quarterly total current liabilities is $15.30 million, with the most recent change of +$3.55 million (+30.20%) on September 30, 2024.
- Over the past year, AVXL quarterly current liabilities has increased by +$3.55 million (+30.20%).
- AVXL quarterly current liabilities is now at all-time high.
Performance
AVXL Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
AVXL Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +22.1% | +30.2% |
| 3 y3 years | +41.7% | +41.7% |
| 5 y5 years | +203.7% | +41.7% |
AVXL Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +49.8% | at high | +89.6% |
| 5 y | 5-year | at high | +203.7% | at high | +180.1% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Anavex Life Sciences Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | $15.30 M(+22.1%) | $15.30 M(+30.2%) |
| Jun 2024 | - | $11.75 M(+23.0%) |
| Mar 2024 | - | $9.56 M(-23.5%) |
| Dec 2023 | - | $12.49 M(-0.3%) |
| Sep 2023 | $12.53 M(+22.7%) | $12.53 M(+13.4%) |
| Jun 2023 | - | $11.06 M(-21.2%) |
| Mar 2023 | - | $14.02 M(+5.8%) |
| Dec 2022 | - | $13.25 M(+29.7%) |
| Sep 2022 | $10.21 M(-5.4%) | $10.21 M(+7.7%) |
| Jun 2022 | - | $9.48 M(+17.5%) |
| Mar 2022 | - | $8.07 M(-23.3%) |
| Dec 2021 | - | $10.53 M(-2.5%) |
| Sep 2021 | $10.80 M(+47.8%) | $10.80 M(+16.4%) |
| Jun 2021 | - | $9.27 M(+19.4%) |
| Mar 2021 | - | $7.76 M(-3.4%) |
| Dec 2020 | - | $8.03 M(+10.0%) |
| Sep 2020 | $7.31 M(+45.0%) | $7.31 M(+5.1%) |
| Jun 2020 | - | $6.95 M(+11.6%) |
| Mar 2020 | - | $6.23 M(+14.0%) |
| Dec 2019 | - | $5.46 M(+8.4%) |
| Sep 2019 | $5.04 M(+29.7%) | $5.04 M(+16.2%) |
| Jun 2019 | - | $4.34 M(-31.9%) |
| Mar 2019 | - | $6.37 M(+30.7%) |
| Dec 2018 | - | $4.88 M(+25.5%) |
| Sep 2018 | $3.88 M(+8.4%) | $3.88 M(+21.0%) |
| Jun 2018 | - | $3.21 M(-6.1%) |
| Mar 2018 | - | $3.42 M(+22.1%) |
| Dec 2017 | - | $2.80 M(-21.9%) |
| Sep 2017 | $3.58 M(+12.3%) | $3.58 M(+146.4%) |
| Jun 2017 | - | $1.45 M(-31.4%) |
| Mar 2017 | - | $2.12 M(-3.4%) |
| Dec 2016 | - | $2.19 M(-31.2%) |
| Sep 2016 | $3.19 M(+19.9%) | $3.19 M(+46.9%) |
| Jun 2016 | - | $2.17 M(-10.7%) |
| Mar 2016 | - | $2.43 M(-4.0%) |
| Dec 2015 | - | $2.53 M(-4.8%) |
| Sep 2015 | $2.66 M | $2.66 M(+96.8%) |
| Jun 2015 | - | $1.35 M(-11.6%) |
| Mar 2015 | - | $1.53 M(+7.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | - | $1.42 M(-1.6%) |
| Sep 2014 | $1.44 M(-26.2%) | $1.44 M(-24.3%) |
| Jun 2014 | - | $1.90 M(+1.1%) |
| Mar 2014 | - | $1.88 M(+3.4%) |
| Dec 2013 | - | $1.82 M(-6.7%) |
| Sep 2013 | $1.95 M(-32.4%) | $1.95 M(-45.1%) |
| Jun 2013 | - | $3.56 M(+3.5%) |
| Mar 2013 | - | $3.44 M(+0.8%) |
| Dec 2012 | - | $3.41 M(+18.0%) |
| Sep 2012 | $2.89 M(+114.7%) | $2.89 M(+30.1%) |
| Jun 2012 | - | $2.22 M(-28.8%) |
| Mar 2012 | - | $3.12 M(+21.6%) |
| Dec 2011 | - | $2.57 M(+90.7%) |
| Sep 2011 | $1.35 M(-59.1%) | $1.35 M(-40.3%) |
| Jun 2011 | - | $2.25 M(+74.1%) |
| Mar 2011 | - | $1.29 M(+121.9%) |
| Dec 2010 | - | $582.90 K(-82.3%) |
| Sep 2010 | $3.29 M(-19.7%) | $3.29 M(-58.3%) |
| Jun 2010 | - | $7.88 M(+68.0%) |
| Mar 2010 | - | $4.69 M(+5.9%) |
| Dec 2009 | - | $4.43 M(+8.1%) |
| Sep 2009 | $4.10 M(+78.2%) | $4.10 M(+17.0%) |
| Jun 2009 | - | $3.50 M(+7.1%) |
| Mar 2009 | - | $3.27 M(+18.6%) |
| Dec 2008 | - | $2.76 M(+20.0%) |
| Sep 2008 | $2.30 M(+397.2%) | $2.30 M(+28.4%) |
| Jun 2008 | - | $1.79 M(+61.7%) |
| Mar 2008 | - | $1.11 M(+122.1%) |
| Dec 2007 | - | $498.70 K(+7.8%) |
| Sep 2007 | $462.50 K(+1551.8%) | $462.50 K(+2.3%) |
| Jun 2007 | - | $451.90 K(+113.3%) |
| Mar 2007 | - | $211.90 K(+556.0%) |
| Dec 2006 | - | $32.30 K(+15.4%) |
| Sep 2006 | $28.00 K(+3.7%) | $28.00 K(-5.4%) |
| Jun 2006 | - | $29.60 K(-21.9%) |
| Mar 2006 | - | $37.90 K(+14.2%) |
| Dec 2005 | - | $33.20 K(+23.0%) |
| Sep 2005 | $27.00 K(+980.0%) | $27.00 K |
| Sep 2004 | $2500.00 | - |
FAQ
- What is Anavex Life Sciences annual total current liabilities?
- What is the all time high annual current liabilities for Anavex Life Sciences?
- What is Anavex Life Sciences annual current liabilities year-on-year change?
- What is Anavex Life Sciences quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Anavex Life Sciences?
- What is Anavex Life Sciences quarterly current liabilities year-on-year change?
What is Anavex Life Sciences annual total current liabilities?
The current annual current liabilities of AVXL is $15.30 M
What is the all time high annual current liabilities for Anavex Life Sciences?
Anavex Life Sciences all-time high annual total current liabilities is $15.30 M
What is Anavex Life Sciences annual current liabilities year-on-year change?
Over the past year, AVXL annual total current liabilities has changed by +$2.77 M (+22.10%)
What is Anavex Life Sciences quarterly total current liabilities?
The current quarterly current liabilities of AVXL is $15.30 M
What is the all time high quarterly current liabilities for Anavex Life Sciences?
Anavex Life Sciences all-time high quarterly total current liabilities is $15.30 M
What is Anavex Life Sciences quarterly current liabilities year-on-year change?
Over the past year, AVXL quarterly total current liabilities has changed by +$3.55 M (+30.20%)